<p>Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations.</p>

Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations.

The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.

Share The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations

Sign up to save your podcasts

The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations

The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations

More shows like Lung Cancer Update

Gastrointestinal Cancer Update

Prostate Cancer Update

Breast Cancer Update

Gynecologic Oncology Update

Hematologic Oncology Update

Dermatologic Oncology Update

Lung Cancer CancerCare Connect Education Workshops

NEJM This Week

Journal of Clinical Oncology (JCO) Podcast

Research To Practice | Oncology Videos

ASCO Daily News

The Long Run with Luke Timmerman

ASCO Guidelines

Lung Cancer Considered

Oncology Today with Dr Neil Love

Business Of Biotech

Two Onc Docs